Zydus Lifesciences vs Alkem Laboratories: Share Price, Comparison and Key Differences
- August 10, 2026
- Posted by: Neeraj Pandey
- Category: News
Zydus Lifesciences MCap Rs 1,10,349 Cr, PE 21.54x, ROE 18.59%, D/E 0.46. Alkem Laboratories MCap Rs 67,057 Cr, PE 28.52x, ROE 16.66%, D/E 0.15, Div 0.94%.
Zydus Lifesciences vs Alkem Laboratories is a comparison mid-to-large pharma investors look up when evaluating two of India’s most profitable domestic pharmaceutical companies. Zydus Lifesciences (formerly Cadila Healthcare) is an Ahmedabad-based pharma company with a strong branded India business, growing US generics, and a biologics and biosimilar pipeline. Alkem Laboratories is a Mumbai-based pharma company known for its dominant position in India’s branded generic prescription market – particularly antibiotics (Taxim-O, Pan-D) and consumer health.
This Zydus Lifesciences vs Alkem Laboratories article covers reach and market position, key products, latest declared results and stock valuation. The Zydus Lifesciences vs Alkem Laboratories data below is sourced from Groww and public company filings and reflects the most recently available information at the time of writing.
Zydus Lifesciences vs Alkem Laboratories: Reach and Market Position
On the Zydus Lifesciences side of the Zydus Lifesciences vs Alkem Laboratories comparison, Zydus Lifesciences serves India with branded generics across gastroenterology, cardiology, CNS, diabetes and skin care, and exports to the US, EU and emerging markets. Market capitalisation is Rs 1,10,349 Cr.
Click Here – Get Free Investment Predictions
On the Alkem Laboratories side of the Zydus Lifesciences vs Alkem Laboratories comparison, Alkem Laboratories serves India with one of the largest field forces in branded generic pharmaceuticals – anti-infectives, gastrointestinal, pain management and cardiac – and has a significant US generic exports business. Market capitalisation is Rs 67,057 Cr.
Zydus Lifesciences vs Alkem Laboratories: Key Products and Business Mix
In the Zydus Lifesciences vs Alkem Laboratories product comparison, Zydus Lifesciences offers: Zydus earns from Indian branded generics, US generic launches, API manufacturing and international markets. PE is 21.54x, ROE 18.59 percent, D/E 0.46. Zydus is 1.6 times larger than Alkem by market cap.
For Alkem Laboratories in this Zydus Lifesciences vs Alkem Laboratories breakdown: Alkem earns from India branded generics (No. 2 by value in India IPM) and US generics. EPS is Rs 196.64. PE is 28.52x, ROE 16.66 percent, D/E 0.15, Div 0.94 percent.
Zydus Lifesciences vs Alkem Laboratories: Latest Results
The Zydus Lifesciences vs Alkem Laboratories results for Zydus Lifesciences: Zydus Lifesciences has a market cap of Rs 1,10,349 Cr and PE of 21.54x. ROE is 18.59 percent. Zydus is cheaper on PE than Alkem despite a higher ROE.
The Zydus Lifesciences vs Alkem Laboratories results for Alkem Laboratories: Alkem Laboratories has a market cap of Rs 67,057 Cr and PE of 28.52x. ROE is 16.66 percent. Alkem is more expensive on PE, partly reflecting its premium India market share positioning and Taxim-O (cefixime) brand dominance.
Compare Zydus Lifesciences and Alkem Laboratories Fundamentals on the Univest Screener
Zydus Lifesciences vs Alkem Laboratories: Stock and Valuation
The Zydus Lifesciences vs Alkem Laboratories stock comparison uses the latest available market data from Groww. Investors tracking Zydus Lifesciences vs Alkem Laboratories should verify current prices on NSE or BSE before trading.
Zydus Lifesciences vs Alkem Laboratories at current valuations: Zydus trades at Rs 1,10,349 Cr market cap, PE 21.54x, ROE 18.59 percent. Alkem trades at Rs 67,057 Cr market cap, PE 28.52x, ROE 16.66 percent, Div 0.94 percent. Zydus is cheaper on PE with a higher ROE. Alkem commands a premium for its India branded pharma dominance.
Zydus Lifesciences vs Alkem Laboratories: Quick Comparison Table
The Zydus Lifesciences vs Alkem Laboratories comparison table below summarises the key metrics covered in this article side by side.
| Parameter | Zydus Lifesciences | Alkem Laboratories |
|---|---|---|
| Sector | Branded generics + US + biologics (pan-India) | Branded generics (No. 2 India IPM) + US generics |
| Market Cap | Rs 1,10,349 Cr | Rs 67,057 Cr |
| P/E Ratio | 21.54x | 28.52x |
| ROE | 18.59% | 16.66% |
| Debt to Equity | 0.46 | 0.15 |
| Dividend | 0.09% yield | 0.94% yield |
| Key Brand/Segment | India branded generics + US + biologics | Taxim-O, Pan-D; India anti-infective leader |
Conclusion
The Zydus Lifesciences vs Alkem Laboratories comparison above covers the key data points on reach, products, results and valuation. Zydus Lifesciences vs Alkem Laboratories covers two of India’s most successful branded generics companies. Zydus is a more diversified pharma company with India, US and biologics exposure. Alkem has a dominant India branded prescription franchise with one of the industry’s largest field forces. Zydus Lifesciences vs Alkem Laboratories investors should review India prescription growth, US ANDA pipeline, NDA filings, USFDA inspection status and domestic branded volume growth. Zydus Lifesciences vs Alkem Laboratories both benefit from India’s healthcare growth – consult a SEBI-registered advisor.
Download the Univest iOS App or Univest Android App to track Zydus Lifesciences and Alkem Laboratories live price and get daily stock recommendations.
Disclaimer: Data and figures in this article are sourced from publicly available information, including company results filings and exchange data, and are current as of the time of writing. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
What is Zydus Lifesciences known for?
Ans. Zydus Lifesciences (formerly Cadila Healthcare) is known for its India branded generic franchises in gastrointestinal, cardiovascular, CNS and dermatology, along with growing US generic business and a pioneering DNA COVID vaccine ZyCoV-D.
What is Alkem’s top brand?
Ans. Alkem’s top brands include Taxim-O (cefixime antibiotic – India’s largest-selling branded prescription drug for years), Pan-D (pantoprazole + domperidone), Clavam (amoxicillin-clavulanate) and Zofer (ondansetron).
Which is larger, Zydus or Alkem?
Ans. Zydus Lifesciences is larger at Rs 1,10,349 Cr versus Alkem at Rs 67,057 Cr – approximately 1.6 times larger.
Does Alkem pay dividends?
Ans. Yes. Alkem pays a dividend yield of approximately 0.94 percent.
What is the India Pharmaceutical Market (IPM)?
Ans. The India Pharmaceutical Market (IPM) tracks total prescription drug sales in India. The market is measured by branded generic companies based on their prescription volumes tracked by IQVIA (formerly IMS Health).
Are Zydus and Alkem in Nifty 50?
Ans. Neither is in Nifty 50. Both are tracked in Nifty Pharma and Nifty 500 indices.
What is a branded generic?
Ans. A branded generic is a drug sold under a company brand name (e.g., Taxim-O by Alkem) that contains the same active pharmaceutical ingredient as the original innovator but is sold as a generic after the innovator patent expires.
